In the last 20 years, noninvasive serum biomarkers to identify liver fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) have been developed, validated against liver biopsy (the gold standard for determining the presence of liver fibrosis) and made available for clinicians to use to identify ≥F3 liver fibrosis. The aim of this review is firstly to focus on the current use of widely available biomarkers and their performance for identifying ≥F3. Secondly, we discuss whether noninvasive biomarkers have a role in identifying F2, a stage of fibrosis that is now known to be a risk factor for cirrhosis and overall mortality. We also consider whether machine learning algorithms offer a better alternative for identifying individuals with ≥F2 fibrosis. Thirdly, we summarise the utility of noninvasive serum biomarkers for predicting liver related outcomes (e.g., ascites and hepatocellular carcinoma) and non-liver related outcomes (e.g., cardiovascular-related mortality and extra hepatic cancers). Finally, we examine whether serial measurement of biomarkers can be used to monitor liver disease, and whether the use of noninvasive biomarkers in drug trials for non-alcoholic steatohepatitis can accurately, compared to liver histology, monitor liver fibrosis progression/regression. We conclude by offering our perspective on the future of serum biomarkers for the detection and monitoring of liver fibrosis in NAFLD.
Citations
Citations to this article as recorded by
Assessing Nutritional Factors for Metabolic Dysfunction-Associated Steatotic Liver Disease via Diverse Statistical Tools Yea-Chan Lee, Hye Sun Lee, Soyoung Jeon, Yae-Ji Lee, Yu-Jin Kwon, Ji-Won Lee Diabetes & Metabolism Journal.2026; 50(1): 178. CrossRef
Structure–Activity Relationship Guided Design of a Highly Sensitive Turn‐on Fluorescent Probe for Imaging Inflammation‐Associated‐HOCl in Early Liver Fibrosis Xinrui Yang, Yuliang Jiang, Shuqi Wang, Yue Fang, Bing Li, Jinlong Li, Wei Li, Zhihui Dai Chemistry – A European Journal.2026;[Epub] CrossRef
Performance of three clinical scores for steatosis and steatohepatitis and their interaction with metabolic syndrome in obese individuals Giovani Schulte Farina, Bárbara Brambilla, Emanuelle Mendonça Pandolfo, Laura Kalil Nader Lazzaretti, Stéfano Mateus Schio Kuiava, Ana Maria Graciolli, Vitória Maria Kriger, Carlos Henrique Dal Bem Fistarol, Augusto Cardoso Sgarioni, Henrique Prataviera G World Journal of Hepatology.2026;[Epub] CrossRef
MASLD biomarker discovery: evaluating lipidomics techniques across disease progression Sally Ibrahim Hassanein Molecular Biology Reports.2026;[Epub] CrossRef
The relationship between triglyceride-glucose index, triglyceride-glucose-body mass index, and the severity of hepatic steatosis and liver fibrosis in patients with MASLD: a cross-sectional study Xingye Wu, Jiacheng Mo, Jinming Yu, Shisi Zhang, Dan Zheng, Xiaoying Chen, Ruibing Qi, Jiaqin Jiang, Kun Ye, Zhengming Li Frontiers in Nutrition.2026;[Epub] CrossRef
Metabolic dysfunction associated steatotic liver disease: mechanisms, diagnosis, and management in adults Tina Reinson, Josh Bilson, Caroline Childs, Ryan M Buchanan, Giovanni Targher, Christopher D Byrne BMJ Medicine.2026; 5(1): e002038. CrossRef
Bioinformatics and Immunohistochemistry Reveal the Diagnostic and Mechanistic Role of the Cuproptosis‐Related Genes SMOC2/THY1 in Liver Fibrosis Ranyan Gao, Hongliang Chen, Jiaxin Wang, Lingyi Xu, Fengchun Li, Xinyu Jiang, Xinyu Geng, Ning Li, Ram Prasad Chaulagain, Babalola Deborah Oluwaseun, Wanwei Li, Shizhu Jin Journal of Cellular and Molecular Medicine.2026;[Epub] CrossRef
Transcriptomic and Proteomic Analyses Identify THBS2, VWF, NFASC, and AKR1B10 as Diagnostic Biomarkers for Advanced Fibrosis in NAFLD Shan Ding, Yiqing Liu, Zhi Liu, Fulu Chu, Bingru Lu, Li Xu Journal of Inflammation Research.2026; Volume 19: 1. CrossRef
Three-Dimensional In Situ Sensing and Spatiotemporal Imaging Analysis of Dual Targets in Steatotic Liver Disease Meiqi Song, Ke Shen, Zhuo Liu, Jinghui Zhang, Congcong Jiang, Qinghua Hao, Wei Shen, Hian Kee Lee, Sheng Tang Analytical Chemistry.2026; 98(22): 16355. CrossRef
From FIB-4 to the Artificial Intelligence Era: The Evolution of Non-Invasive Tools (NITs) for Tailored Risk Stratification in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Mario Romeo, Fiammetta Di Nardo, Claudio Basile, Carmine Napolitano, Paolo Vaia, Luigi Di Puorto, Mattia Indipendente, Alessia De Gregorio, Marcello Dallio, Alessandro Federico Livers.2026; 6(4): 71. CrossRef
Peroxisome Proliferator-Activated Receptor (PPAR) Agonists in Chronic Liver Diseases: Translating Mechanistic Insights into Clinical Practice and Future Perspectives Mario Romeo, Claudio Basile, Andrea Imperatore, Giambattista Mozzi, Fiammetta Di Nardo, Carmine Napolitano, Paolo Vaia, Luigi Di Puorto, Mattia Indipendente, Marcello Dallio, Alessandro Federico Cells.2026; 15(14): 1292. CrossRef
Liver Cancer Risk Across Metabolic Dysfunction-Associated Steatotic Liver Disease and/or Alcohol: A Nationwide Study Byungyoon Yun, Heejoo Park, Sang Hoon Ahn, Juyeon Oh, Beom Kyung Kim, Jin-Ha Yoon American Journal of Gastroenterology.2025; 120(2): 410. CrossRef
Value of Mac-2 Binding Protein Glycosylation Isomer (M2BPGi) in Assessing Liver Fibrosis in Metabolic Dysfunction-Associated Liver Disease: A Comprehensive Review of its Serum Biomarker Role Mohammadjavad Sotoudeheian Current Protein & Peptide Science.2025; 26(1): 6. CrossRef
Association between the triglyceride-glucose index and liver fibrosis in adults with metabolism-related fatty liver disease in the United States: a cross-sectional study of NHANES 2017–2020 Yuou Ying, Yuan Ji, Ruyi Ju, Jinhan Chen, Mingxian Chen BMC Gastroenterology.2025;[Epub] CrossRef
Essential tools for assessing advanced fibrosis in metabolic dysfunction-associated steatotic liver disease: Editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fib Won Sohn Clinical and Molecular Hepatology.2025; 31(1): 277. CrossRef
The hepatocellular model of fatty liver disease: from current imaging diagnostics to innovative proteomics technologies Renee Hernandez, Natasha S. Garcia-Rodriguez, Marco A. Arriaga, Ricardo Perez, Auwal A. Bala, Ana C. Leandro, Vince P. Diego, Marcio Almeida, Jason G. Parsons, Eron G. Manusov, Jacob A. Galan Frontiers in Medicine.2025;[Epub] CrossRef
Does the hepatologist still need to rely on aminotransferases in clinical practice? A reappraisal of the role of a classic biomarker in the diagnosis and clinical management of chronic liver diseases Patrizia Burra, Calogero Cammà, Pietro Invernizzi, Fabio Marra, Maurizio Pompili Annals of Hepatology.2025; 30(1): 101900. CrossRef
Reply to correspondence on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023” Jeayeon Park, Su Jong Yu Clinical and Molecular Hepatology.2025; 31(2): e221. CrossRef
Manganese-based type I collagen-targeting MRI probe for in vivo imaging of liver fibrosis Chunxiang Zhang, Hua Ma, Daniel DeRoche, Eric M. Gale, Pamela Pantazopoulos, Nicholas J. Rotile, Himashinie Diyabalanage, Valerie Humblet, Peter Caravan, Iris Y. Zhou npj Imaging.2025;[Epub] CrossRef
Identification of hub gene for the pathogenic mechanism and diagnosis of MASLD by enhanced bioinformatics analysis and machine learning Hong Lu, Ziyong Mao, Mengyao Zheng, Min Zhang, Heqing Huang, Yiling Chen, Long Lv, Zutao Chen, Akif Altınbas, PLOS One.2025; 20(5): e0324972. CrossRef
Mechanism-guided drug development and treatment for liver fibrosis: a clinical perspective Xiangchang Zeng, Deliang Huang, Zhibin Zhu, Qingxian Cai, Yang Yang, Hongzhou Lu, Jun Chen Frontiers in Pharmacology.2025;[Epub] CrossRef
Obesity as a mediator in the association between urinary polycyclic aromatic hydrocarbon exposure and liver fibrosis risk in US adults Wang Guo, Beizhu Ye, Xiaoli Ma, Jinying Liu, Yanqin Yue, Xingyuan Yang, Jian Hou, Xiuling Li, Xiaoying Luo Environmental Science: Processes & Impacts.2025; 27(7): 2082. CrossRef
A multi-biomarker panel for non-invasive diagnosis, risk stratification, subtype identification, and therapeutic targeting in NAFLD: bioinformatics and experimental insights Kanglong Zhang, Yiming Gan, Yihua Chen, Zhiwei Jiang, Qiao Lei, Shuqin Yu, Linwei Ran, Jie Zheng, Guoxin Hu Biochemical and Biophysical Research Communications.2025; 779: 152403. CrossRef
Application of Machine Learning Models in Predicting Non-Alcoholic Fatty Liver Disease Among Inactive Chronic Hepatitis B Patients: A Cross-Sectional Analysis Abdullah M. Al-Alawi, Amna S. Al-Balushi, Halima H. Al-Shuaili, Dalia A. Mahmood, Said A. Al-Busafi Journal of Clinical Medicine.2025; 14(14): 5042. CrossRef
Small-molecule fluorescent probe for bioimaging of organ fibrosis: progress, challenges and prospects Jinlong Li, Chen Liu, Xinrui Yang, Na Tian, Dinghao Pan, Shuqi Wang, Wei Li, Zhihui Dai Biosensors and Bioelectronics.2025; 288: 117822. CrossRef
A Perfect MASH Comparing Resmetirom and GLP-1 Agonists for Metabolic-Associated Steatohepatitis Joanne Lin, Victoria Green, Aalam Sohal, Marina Roytman Journal of Clinical Gastroenterology.2025; 59(10): 923. CrossRef
Exploring the Relationship Between Insulin Resistance, Liver Health, and Restrictive Lung Diseases in Type 2 Diabetes Mani Roshan, Christian Mudrack, Alba Sulaj, Ekaterina von Rauchhaupt, Thomas Fleming, Lukas Schimpfle, Lukas Seebauer, Viktoria Flegka, Valter D. Longo, Elisabeth Kliemank, Stephan Herzig, Anna Hohneck, Zoltan Kender, Julia Szendroedi, Stefan Kopf Journal of Personalized Medicine.2025; 15(8): 340. CrossRef
Comparative evaluation of FIB-3 and FIB-4 indices for liver fibrosis screening in workplace-based health checkups Kota Fukai, Shoko Nakazawa, Kosuke Sakai, Yuko Furuya, Yuya Watanabe, Toru Honda, Takeshi Hayashi, Toru Nakagawa, Masaaki Korenaga, Masayuki Tatemichi Journal of Occupational Health.2025;[Epub] CrossRef
Characteristics of Metabolic Dysfunction-Associated Steatotic Liver Disease and Its Risk for Hepatic Fibrosis in 476,124 Korean Adults: A Cross-Sectional Study Da Yeon Lee, Ji-Hee Ko, Han-Na Jang, Sun Joon Moon, Hye-Mi Kwon, Se Eun Park, Cheol-Young Park, Won-Young Lee, Ki-Won Oh, Eun-Jung Rhee Endocrinology and Metabolism.2025; 40(4): 648. CrossRef
Non-invasive assessment of liver fibrosis in MASLD: the need of sex-adjusted scores Fabio Novielli, Carlo De Matteis, Antonio Moschetta, Lucilla Crudele Expert Review of Gastroenterology & Hepatology.2025; 19(10): 1081. CrossRef
Comparison of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Steatotic Liver Disease Yunmi Ko, Moon Haeng Hur, Youngsu Park, Jeayeon Park, Hyunjae Shin, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim Gut and Liver.2025; 19(5): 758. CrossRef
Racial, Ethnic and Age Disparities in Liver Fibrosis Screening Using Fibrosis Score Measures: A Critical Review of Diagnostic Equity in Liver Disease Ethan Shamsian, Michael Bebawy, Zachary Israeli, Mahinaz Mohsen, Rohan Karkra, Steven Rella, Raphael Shankman, Paul Gaglio Livers.2025; 5(4): 51. CrossRef
From steatosis to cirrhosis: the role of obesity in the progression of liver disease Klaudia Nowak, Maria Paluch, Maja Cudzik, Klaudia Syska, Wiktoria Gawlikowska, Jakub Janczura Journal of Diabetes & Metabolic Disorders.2025;[Epub] CrossRef
Gut microbiota dysbiosis and the gut–liver–brain axis: Mechanistic insights into hepatic encephalopathy Priyanka Manothiya, Debabrata Dash, Raj Kumar Koiri Medicine in Microecology.2025; 26: 100157. CrossRef
Non-Alcoholic Fatty Liver Disease in Outpatient Practice of Southern Russia: A Multicenter Study of 480 Patients Kamila Magomedzhamilievna Kurbanova, Karina Vladimirovna Yakovleva, Suvanet Fazilovna Magaramova, Dayana Anzorovna Khabekirova, Fidan Talib Kizi Mastalieva, Karina Viktorovna Lokhmatova, Alina Andreevna Goloveshko, Alina Manvelovna Grigoryan, Natalia Alek Journal of Biochemical Technology.2025; 16(4): 146. CrossRef
The interplay of metabolic dysfunction‐associated fatty liver disease and viral hepatitis on liver disease severity: A large community‐based study in a viral endemic area Chung‐Feng Huang, Po‐Cheng Liang, Pei‐Chien Tsai, Yu‐Ju Wei, Ching‐I Huang, Chih‐Wen Wang, Tyng‐Yuan Jang, Ming‐Lun Yeh, Po‐Yao Hsu, Ming‐Yen Hsieh, Yi‐Hung Lin, Chia‐Yen Dai, Wan‐Long Chuang, Jee‐Fu Huang, Ming‐Lung Yu Journal of Gastroenterology and Hepatology.2024; 39(1): 193. CrossRef
Performance of noninvasive seromarkers in predicting liver fibrosis among MAFLD patients with or without viral hepatitis Chung‐Feng Huang, Po‐Cheng Liang, Chih‐Wen Wang, Tyng‐Yuan Jang, Po‐Yao Hsu, Pei‐Chien Tsai, Yu‐Ju Wei, Ming‐Lun Yeh, Ming‐Yen Hsieh, Yi‐Hung Lin, Chao‐Kuan Huang, Chia‐Yen Dai, Jee‐Fu Huang, Wan‐Long Chuang, Ming‐Lung Yu The Kaohsiung Journal of Medical Sciences.2024; 40(4): 374. CrossRef
The Portal Venous Pulsatility Index and Main Portal Vein Diameter as Surrogate Markers for Liver Fibrosis in Nonalcoholic Fatty Liver Disease and Metabolic-Dysfunction-Associated Steatotic Liver Disease Jaejun Lee, Seungmyeon Choi, Seong-Hyun Cho, Hyun Yang, Pil-Soo Sung, Si-Hyun Bae Diagnostics.2024; 14(4): 393. CrossRef
Proposal of a Novel Serological Algorithm Combining FIB-4 and Serum M2BPGi for Advanced Fibrosis in Nonalcoholic Fatty Liver Disease Sang Yi Moon, Yang Hyun Baek, Se Young Jang, Dae Won Jun, Ki Tae Yoon, Young Youn Cho, Hoon Gil Jo, Ae Jeong Jo Gut and Liver.2024; 18(2): 283. CrossRef
Neither hepatic steatosis nor fibrosis is associated with clinical outcomes in patients with intestinal Behçet’s disease Hye Kyung Hyun, Jihye Park, Soo Jung Park, Jae Jun Park, Tae Il Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim, Jae Hee Cheon European Journal of Gastroenterology & Hepatology.2024; 36(4): 445. CrossRef
Evolutive Models, Algorithms and Predictive Parameters for the Progression of Hepatic Steatosis Marinela Sînziana Tudor, Veronica Gheorman, Georgiana-Mihaela Simeanu, Adrian Dobrinescu, Vlad Pădureanu, Venera Cristina Dinescu, Mircea-Cătălin Forțofoiu Metabolites.2024; 14(4): 198. CrossRef
Plasma ALS and Gal-3BP differentiate early from advanced liver fibrosis in MASLD patients David Pérez Compte, Lucas Etourneau, Anne-Marie Hesse, Alexandra Kraut, Justine Barthelon, Nathalie Sturm, Hélène Borges, Salomé Biennier, Marie Courçon, Marc de Saint Loup, Victoria Mignot, Charlotte Costentin, Thomas Burger, Yohann Couté, Christophe Bru Biomarker Research.2024;[Epub] CrossRef
Aspartate Aminotransferase to Platelet Ratio Index (APRI) as a Predictor of Metabolic Syndrome (MetS) Development in Individuals With Type 2 Diabetes Mellitus Amir Jalisi, Rijad Jahić, Avdo Kurtović, Miralem Đešević, Azra Husić-Selimović, Enisa Hodžić, Edina Lazović Salčin, Orhan Lepara, Almir Fajkić Cureus.2024;[Epub] CrossRef
Galectin-3 and Severity of Liver Fibrosis in Metabolic
Dysfunction-Associated Fatty Liver Disease Mohammadjavad Sotoudeheian Protein & Peptide Letters.2024; 31(4): 290. CrossRef
Vibration-controlled transient elastography for significant fibrosis in treatment-naïve chronic hepatitis B patients: A systematic review and meta-analysis Mi Na Kim, Jihyun An, Eun Hwa Kim, Hee Yeon Kim, Han Ah Lee, Jung Hwan Yu, Young-Joo Jin, Young Eun Chon, Seung Up Kim, Dae Won Jun, Ji Won Han, Miyoung Choi Clinical and Molecular Hepatology.2024; 30(Suppl): S106. CrossRef
Diagnostic accuracy of the Fibrosis-4 index for advanced liver fibrosis in nonalcoholic fatty liver disease with type 2 diabetes: A systematic review and meta-analysis Ji Won Han, Hee Yeon Kim, Jung Hwan Yu, Mi Na Kim, Young Eun Chon, Ji Hyun An, Young-Joo Jin, Miyoung Choi, Seung Up Kim, Han Ah Lee, Dae Won Jun Clinical and Molecular Hepatology.2024; 30(Suppl): S147. CrossRef
Elevated serum growth differentiation factor 15 and decorin predict the fibrotic progression of metabolic dysfunction-associated steatotic liver disease Jae Seung Chang, Jhii-Hyun Ahn, Moon Young Kim, Kyu-Sang Park Scientific Reports.2024;[Epub] CrossRef
Metabolomic Hallmarks of Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease Diren Beyoğlu, Yury V. Popov, Jeffrey R. Idle International Journal of Molecular Sciences.2024; 25(23): 12809. CrossRef
Non-invasive biomarkers of liver fibrosis in non-alcoholic fatty liver disease Maamon Basheer, Mohamed Naffaa, Nimer Assy Clinical and Molecular Hepatology.2023; 29(2): 398. CrossRef
Liver fibrosis markers and all cause mortality in people with type 2 diabetes: A population based study (The Ayrshire Diabetes Outcomes Cohort (ADOC) Study) Andrew Collier, Christopher Curran, Lyall Cameron, Sarah H. Wild, Christopher D. Byrne Diabetes, Obesity and Metabolism.2023; 25(9): 2659. CrossRef
Identification of individuals at risk of hepatocellular carcinoma: screening for clinically significant liver fibrosis in patients with T2DM Tina Reinson, Ryan M Buchanan, Christopher D Byrne Expert Review of Endocrinology & Metabolism.2023; 18(5): 355. CrossRef
Non-alcoholic fatty liver disease: Immunological mechanisms and current treatments Lucy Petagine, Mohammed Gulrez Zariwala, Vinood B Patel World Journal of Gastroenterology.2023; 29(32): 4831. CrossRef
Us Fda Public Meeting: Identification of Concepts and Terminology for Multicomponent Biomarkers Abena S Agyeman, Abbas Bandukwala, Khaled Bouri, Jessica Hawes, Daniel M Krainak, Samir Lababidi, William B Mattes, Elena V Mishina, Phillip Turfle, Sue-Jane Wang, Theresa Thekkudan Biomarkers in Medicine.2023; 17(11): 523. CrossRef
The Role of the Fatty Liver Index (FLI) in the Management of Non-Alcoholic Fatty Liver Disease: A Systematic Review Teodora Biciusca, Sorina Ionelia Stan, Mara Amalia Balteanu, Ramona Cioboata, Alice Elena Ghenea, Suzana Danoiu, Ana-Maria Bumbea, Viorel Biciusca Diagnostics.2023; 13(21): 3316. CrossRef
Novel noninvasive indices for the assessment of liver fibrosis in primary biliary cholangitis Yan Li, Meng-Jun Zhang, Xue-Hong Wang, Su-Hua Li Biomedical Reports.2023;[Epub] CrossRef
First
Prev
